
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
Coverage of the 63rd American Society of Hematology Meeting & Exposition, which took place in a hybrid format.






